Transdermal Gels in the Treatment of Diabetic Neuropathy
Author(s): Hodges Caroline J, Jones Thomas H, Willoughby David L
Issue: Mar/Apr 2000 - Compounding for Diabetes Patients
View All Articles in Issue
Page(s): 91-93
Download in electronic PDF format for $75
Abstract: Diabetic neuropathy refers to a large number of clinical syndromes affecting both the autonomic and peripheral nervous systems and both type 1 and type 2 diabetes patients. In this article, the authors place particular emphasis on the use of ketamine Pluronic lecithin organogels for treating diabetic neuropathy. They also discuss the etiology of diabetic neuropathy, its clinical presentation, pain management (glycemic control, tricyclic antidepressants, anticonvulsants, ketamine and autonomic agents) and provide three brief case reports describing the use of a polymedicine formula . They conclude that medications administered by transdermal gels are a viable option and potentially the most rewarding for a compounding pharmacist, as they allow pain relief with fewer adverse effects. The real challenge is deciding whether the patient should begin with the polymedicine formula or with ketamine 10% and amitriptyline 2%, with additional ingredients added as needed to determine the optimal combination of medications for analgesic effects. More research is needed to determine the best combination of agents.
Related Keywords:
diabetic neuropathy, burning pain, allodynia, hyperpathia, glycemic control, tricyclic antidepressants, gabapentin, ketamine, NMDA receptor antagonist, phantom limb pain, clonidine, baclofen
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Transdermal Gels in the Treatment of Diabetic Neuropathy
Hodges Caroline J, Jones Thomas H, Willoughby David L
|
Mar/Apr 2000
Pg. 91-93
|
Profile of a Practice: Ward Drug Company Diabetic Shoppe and Prescription Compounding Center
Vail Jane
|
Jan/Feb 2003
Pg. 21-23
|
Topical Ketamine: A Review of the History, Mechanisms, Uses, Safety, and Future
Rabi Joseph
|
Mar/Apr 2016
Pg. 107-113
|
Compounded Pain Formulations: What is the Evidence?
Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
|
Jul/Aug 2014
Pg. 278-286
|
Compounded Pain Formulations: What is the Evidence?
Asbill Scott, Sweitzer Sarah M, Spigener Shuler, Romero-Sandoval Alfonso
|
Mar/Apr 2024
Pg. 100-109
|
Topical Medications for Orofacial Neuropathic Pain
Bramwell Bethany L
|
May/Jun 2010
Pg. 200-203
|
Chronic Neuropathic Pain: Pharmacological Interventions in New Millennium
Jones Marty
|
Jan/Feb 2000
Pg. 6-15
|
Five Compounds for Treating Diabetes-Related Conditions
Meece Jerry
|
May/Jun 2003
Pg. 170-174
|
Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
|
May/Jun 2010
Pg. 182-192
|
Veterinary Transdermal Medications: A to Z
Davidson Gigi S
|
Mar/Apr 2003
Pg. 106-113
|
Case Report: Wound Care of a Diabetic Foot Ulcer
Wynn Tom
|
Jul/Aug 2004
Pg. 265-267
|
Complications of Diabetes
Key David M
|
Mar/Apr 2000
Pg. 88-90
|
Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm
Allen Loyd V Jr
|
Mar/Apr 2024
Pg. 135
|
Ketamine Hydrochloride 5%, Gabapentin 10%, Clonidine Hydrochloride 0.2%, and Baclofen 2% in Lipoderm
Allen Loyd V Jr
|
May/Jun 2016
Pg. 231
|
Dextromethorphan, an NMDA receptor antagonist, as a Treatment for Pain
Mishkan Emilyn S
|
Sep/Oct 2005
Pg. 339-346
|
Transdermal Gel in the Treatment of Postoperative Pain
Alexander Kayla, Wynn Tom
|
May/Jun 2007
Pg. 181-184
|
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Jul/Aug 2015
Pg. 295-300
|
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Mar/Apr 2024
Pg. 111-116
|
Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel
Allen Loyd V Jr
|
Mar/Apr 2024
Pg. 131
|
Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel
Allen Loyd V Jr
|
Mar/Apr 2011
Pg. 157
|
Return to Top |